San Francisco, Nov 26 The
global amyloidosis
treatment market size is expected to reach USD 6.7 billion by
2025, according to a new report by Grand View Research, Inc., registering a
7.2% CAGR during the forecast period. Several factors such as increased
adoption of novel targeted therapies and transplantations, emergence of
biologics, and rising geriatric population are driving the market.
Amyloidosis
is a group of rare diseases where misfolded aggregates of proteins (amyloids)
buildup in tissues and organs. AL amyloidosis is the most common type of
amyloidosis in U.S., with approximately 3,000 to 4,000 new cases diagnosed
annually. Although in majority of cases, the disease is diagnosed in people
over the age of 60, there are a few cases of people being diagnosed in their
late 20s and about two-thirds of the patients are male.
Among
treatments, chemotherapy held the largest share in 2017, followed by targeted
therapy, and supportive care. However, targeted therapies are expected to
dominate the market in 2025, supported by a strong pipeline and potential
approval of drugs such as Alnylam’s Onpattro, Ionis’ Tegsedi, Johnson &
Johnson’s Darzalex, and Takeda’s Ninlaro.
Stem
cell transplants and targeted therapies are gaining traction in developed
countries. However, amyloidosis cohorts in endemic regions do not have access
to sufficient healthcare infrastructure to ensure prompt diagnosis and
treatment in underdeveloped countries. Chemotherapy and supportive care are
anticipated to lose market share over the forecast period due to adverse side
effects and lower efficacy.
Browse full research report on Amyloidosis Treatment Market:
www.grandviewresearch.com/industry-analysis/amyloidosis-treatment-market
Further key findings from the report suggest:
- An estimated
16,000 people in U.S. suffer from amyloidosis, with approximately 3,000 to
4,000 new cases being reported annually
- U.S.
dominated the global amyloidosis treatment market, with a share of more
than 27.0% in 2017 due to potential launch of pipeline drugs, increased
adoption of novel therapeutics, and high cost of treatment in the country
- Chemotherapy
dominated the amyloidosis treatment market, with a share of about 35.0% in
2017. Targeted therapies are projected to witness double-digit growth
during the forecast period due to multiple product approvals
- Emerging
markets for amyloidosis such as China, Sweden, Portugal, Turkey, South
Africa, Brazil, Mexico, Saudi Arabia, and India are expected to show
attractive growth over the forecast period due to improved healthcare
infrastructure, favorable government policies, increased investment, and
large amyloidosis cohort
- Alnylam, Ionis,
Pfizer, Johnson & Johnson and Takeda are some of the key players
operating in this market
- Currently, 19
products are under evaluation for amyloidosis treatment in various stages
of clinical development. Promising pipeline candidates such as Onpattro,
Vyndaqel, Tegsedi, Darzalex, and Ninlaro are expected to generate
significant revenue upon launch.
Browse more reports of this category
by Grand View Research: www.grandviewresearch.com/industry/pharmaceuticals
Grand
View Research has segmented the global amyloidosis treatment market based on
treatment and country:
Amyloidosis
Treatment Outlook (Revenue, USD Million, 2017 - 2025)
- Chemotherapy
- Supportive
care
- Surgery
- Stem Cell
Transplant
- Targeted
Therapy
Amyloidosis
Treatment Country Outlook (Revenue, USD Million, 2017 - 2025)
- U.S.
- Japan
- U.K.
- Germany
- France
- Spain
- Italy
Browse press release of this report
by Grand View Research: www.grandviewresearch.com/press-release/global-amyloidosis-treatment-market
About Grand View Research
Grand
View Research, Inc. is a U.S. based market research and consulting company,
registered in the State of California and headquartered in San Francisco.
The company provides syndicated research reports, customized research
reports, and consulting services. To help clients make informed business
decisions, we offer market intelligence studies ensuring relevant and
fact-based research across a range of industries, from technology to chemicals,
materials and healthcare.
For more information:
www.grandviewresearch.com
No comments:
Post a Comment